Free Post Earnings Research Report: Exact Sciences’ Quarterly Revenues Jumped 148.02%

Stock Monitor: Biocept Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free earnings report on Exact Sciences Corp. (NASDAQ: EXAS) (“EXAS”). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EXAS. On February 22, 2018, Exact Sciences reported financial results for the fourth quarter and full year ended December 31, 2017. The Company surpassed analysts’ estimates for revenue as well as earnings in the fourth quarter of 2017. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Biocept, Inc. (NASDAQ: BIOC), which also belongs to the Healthcare sector as the Company Exact Sciences. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=BIOC

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Exact Sciences most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=EXAS

Earnings Highlights and Summary

EXAS’ Laboratory service revenue reached $87.41 million for Q4 FY17, up 148.02% from $35.24 million in Q4 FY16. This exceeded analysts’ consensus estimates of $87.3 million. The Company completed approximately 176,000 Cologuard tests in Q4 FY17, an increase of about 115% from previous year’s corresponding quarter.

During Q4 FY17, EXAS’ cost of sales was $23.5 million compared to $13.87 million in Q4 FY16, reflecting an increase of 69.46%. The Company’s gross profit was $63.91 million for Q4 FY17, which is almost 2.99 times the gross profit of $21.38 million in Q4 FY16. EXAS’ gross margin improved 12.46% to 73.12% in the reported quarter.

EXAS incurred operating expenses of $87.04 million in Q4 FY17, 47.32% higher than $59.09 million in Q4 FY16. The Company’s research and development (R&D) advanced 78.97% to $12.68 million y-o-y, general and administrative (G&A) surged 56.95% to $33.74 million y-o-y, and sales and marketing expenses increased 33.18% to $40.63 million y-o-y in Q4 FY17. EXAS had an operating loss of $23.13 million in the quarter under review, after an operating loss of $37.71 million in the previous year’s same quarter.

EXAS reported a net loss of $21.76 million, or $0.18 per share, in Q4 FY17 compared to a net loss of $37.17 million, or $0.34 per share, in Q4 FY16. Analysts estimated a loss of $0.27 per share for Q4 FY17.

For the year ending December 31, 2017, EXAS’ laboratory service revenues were $265.99 million, up 167.66% from $99.38 million in FY16. The Company screened a total of 571,000 people with Cologuard in FY17. EXAS’ gross profit advanced 244.76% to $186.79 million y-o-y in FY17. The Company incurred an operating loss of $118.31 million in the reported year, after an operating loss of $169.02 million in the previous year. The Company’s net loss narrowed to $114.4 million, or $0.99 per share, in FY17 from $167.22 million, or $1.30 per share, in FY16.

Cash Matters

EXAS had cash and cash equivalents of $77.49 million as on December 31, 2017, 58.40% higher than $48.92 million as on December 31, 2016. The Company’s long-term debt reduced 7.86% to $4.27 million as on December 31, 2017, from $4.63 million as on December 31, 2016.

The Company raised an estimated $671.3 million, net, through an offering of convertible notes in the reported quarter.

Outlook

For full-year 2018, EXAS expects revenue to be in the range of $420 million to $430 million. The Company expects a completed Cologuard test volume of 900,000-920,000 tests during FY18.

Stock Performance Snapshot

April 05, 2018 – At Thursday’s closing bell, Exact Sciences’ stock slightly fell 0.42%, ending the trading session at $40.50.

Volume traded for the day: 2.71 million shares.

Stock performance in the past twelve-month period – up 78.49%

After yesterday’s close, Exact Sciences’ market cap was at $4.79 billion.

The stock is part of the Healthcare sector, categorized under the Medical Laboratories & Research industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 495320